01Purpose and principlesWhat the treatment does and how it fits into care.
Valproate can be effective in bipolar mania, but its reproductive harms have produced unusually specific UK regulatory restrictions. The term covers valproic acid, sodium valproate and semi-sodium valproate, whose licences differ. In bipolar disorder, semi-sodium valproate has the relevant adult mania and continuation licence when lithium is contraindicated or not tolerated. A safety decision therefore requires the exact patient, age, reproductive context, indication and formulation rather than treating valproate as one interchangeable class.
At initiation, current MHRA policy applies to every new patient under 55, male or female. Valproate must not be started unless two specialists independently consider and document that there is no other effective or tolerated treatment, or that compelling reasons mean the reproductive risks do not apply. This is an exception gate, not routine shared prescribing. Verify the latest MHRA collection and use the current risk-acknowledgement material because regulatory details and forms can be updated.
For a woman or girl able to have children, additional Pregnancy Prevention Programme requirements apply. Alternative treatment must be ineffective or not tolerated, pregnancy must be excluded as required, effective contraception and specialist review must be maintained, and the Annual Risk Acknowledgement Form used. Current materials distinguish the initial countersigned decision from later annual reviews, which generally need one specialist, so use the latest form. Maternal pregnancy exposure is associated with approximately 11% major congenital malformations and neurodevelopmental problems in about 30% to 40% of children. For bipolar disorder, valproate must not be used during pregnancy.
Male counselling is distinct. Observational data suggest a possible increase in neurodevelopmental disorders among children conceived when the father used valproate in the preceding three months, but confounding remains and causality is not confirmed. As a precaution, advise effective contraception during treatment and for at least three months after stopping, and no sperm donation for the same interval. Men planning a family within a year need specialist discussion of treatment alternatives. These precautions can remain relevant after age 55.
Do not create harm through abrupt discontinuation. A person concerned about pregnancy or conception should contact the specialist urgently while continuing the existing regimen until an individual plan is agreed, unless an acute toxicity requires withholding treatment. Monitor weight, blood count and liver function, teach symptoms of liver, pancreatic and blood disorders, review interactions and sedation, and reconsider benefit, risk and documentation at each specialist review.
Key points
- Do not start valproate in a new patient, male or female, under 55 unless two specialists independently agree and document that no other effective or tolerated treatment exists or compelling reasons make reproductive risks inapplicable.
- For women and girls able to have children, valproate is used only when alternatives are ineffective or not tolerated and every Pregnancy Prevention Programme condition is met.
- Valproate is contraindicated for bipolar disorder during pregnancy; suspected pregnancy requires urgent specialist discussion, not abrupt unsupervised stopping.
- Maternal pregnancy exposure is associated with major congenital malformation in about 11% and developmental problems in roughly 30% to 40% of exposed children.
- For men, MHRA precautionary advice recommends effective contraception during treatment and for at least three months afterward and no sperm donation during the same period.
- Men planning a family within the next year should receive specialist review of alternatives; possible paternal neurodevelopmental risk is based on limited observational evidence and causality is not confirmed.
- Existing men under 55 do not require a retrospective two-specialist authorisation solely because they already take valproate, but still need current counselling and treatment review.
- Before treatment record weight or BMI, full blood count and liver function; repeat weight, FBC and liver tests after six months and annually, and do not measure levels routinely without a specific indication.
- Use current MHRA materials, risk-acknowledgement forms and patient card at each required review because sex, age, fertility, partner and regulatory circumstances can change.
- Dispense valproate in the original full pack with outer-box warnings and patient information wherever required; any exceptional split-pack supply must preserve the mandated safety information.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
The patient has never received valproate and therefore needs the independent two-specialist exception decision before any first prescription.
A woman or girl able to become pregnant requires the full Pregnancy Prevention Programme in addition to general initiation restrictions.
A man using valproate has a pregnancy-capable partner or plans a family, triggering contraception, sperm-donation and specialist-alternative counselling.
A man under 55 already established on valproate needs current counselling and review but not automatic retrospective two-specialist approval solely for continuation.
Abdominal, hepatic, haematological, cognitive or neurological symptoms require urgent targeted assessment rather than waiting for the next scheduled annual test.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Regulatory eligibility reviewFirst step - Why
- Confirm age, new or existing status, indication, alternatives, reproductive context, specialist decisions and current forms.
- Interpretation and limitations
- Treatment proceeds only when every applicable initiation and Pregnancy Prevention Programme condition is documented; one historical form does not cover changed circumstances.
- 02
Pregnancy and contraception assessment - Why
- Establish pregnancy status, ability to become pregnant, contraceptive effectiveness and pregnancy intention sensitively.
- Interpretation and limitations
- Results direct urgent specialist action and programme requirements; reproductive capability and identity should be discussed individually rather than assumed from records.
- 03
Required physical baseline - Why
- Measure weight or BMI, full blood count and liver function before valproate exposure.
- Interpretation and limitations
- Existing liver disease, blood abnormality or metabolic risk changes suitability and establishes a baseline for future adverse-effect trends.
- 04
Scheduled safety surveillance - Why
- Repeat weight or BMI, liver function and full blood count at six months and then annually.
- Interpretation and limitations
- Abnormal liver function or blood dyscrasia requires prompt specialist action; symptoms justify immediate testing regardless of the calendar.
- 05
Indicated plasma valproate level - Why
- Investigate suspected ineffectiveness, poor adherence or toxicity when concentration will change management.
- Interpretation and limitations
- Routine levels are not recommended. A concentration supports but does not replace clinical assessment of response, organ toxicity and exact formulation.
04Treatment approachPreparation, options, escalation and aftercare.
01New patient under 55Apply the two-specialist exception gateFirst stepValproate is proposed for the first time for a male or female patient younger than 55 years.+
- 1Confirm diagnosis, exact product and licence, previous effective and tolerated alternatives and why valproate is being considered now.
- 2AlternativeObtain two independent specialist decisions and documentation that no effective tolerated alternative exists or compelling reasons make reproductive risks inapplicable.
- 3Complete sex-specific acknowledgement, pregnancy-prevention or male counselling materials and baseline tests before the first prescription is supplied.
02Pregnancy-capable patientMaintain every programme conditionA woman or girl able to have children is starting or continuing valproate after alternatives failed or were not tolerated.+
- 1Confirm specialist review, pregnancy status and effective contraception and communicate the quantified fetal and developmental risks in accessible language.
- 2Complete the current Annual Risk Acknowledgement Form and any required countersignature and provide the patient guide and card.
- 3Arrange urgent contact for missed contraception, planned or suspected pregnancy or changed preference and never rely on abrupt self-discontinuation as prevention.
03Male reproductive counsellingAddress conception and fertility riskA man taking or considering valproate could father a child or is planning a family.+
- 1Explain possible impaired fertility and the uncertain observational paternal neurodevelopmental signal without presenting causality as proven.
- 2Advise effective contraception during treatment and for three months after stopping and no sperm donation throughout that interval.
- 3If family planning is expected within a year, arrange specialist alternatives review and supervise any taper so bipolar relapse risk remains managed.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Semi-sodium valproate oral tablets
For an adult manic episode, the product recommends 750 mg daily by mouth in two or three divided doses, increased to the lowest effective dose; the usual total is 1000 to 2000 mg daily, individualised by response.Contraindicated for bipolar disorder in pregnancy and restricted in people under 55; also avoid or seek specialist advice with liver disease, urea-cycle or mitochondrial disorders, pancreatitis risk, blood dyscrasia and major interactions.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Confirm at every specialist review that the current MHRA eligibility, sex-specific counselling, contraception and acknowledgement requirements remain fulfilled.
- Repeat weight or BMI, full blood count and liver function after six months and annually, with immediate testing for compatible hepatic, pancreatic or haematological symptoms.
- Review mood control, sedation, tremor, gait, weight, adherence, formulation, interactions and reproductive goals rather than monitoring safety documents alone.
- Do not order routine plasma levels; reserve a concentration for suspected ineffectiveness, poor adherence or toxicity and interpret it with the clinical state.
- When stopping for a planned treatment change, taper over at least four weeks where clinically possible and monitor closely for manic or depressive relapse.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
New and existing differ
The two-specialist initiation restriction for under-55s must not be incorrectly imposed as a retrospective continuation gate on every established male patient.
Sex assumptions are unsafe
Ask sensitively about reproductive anatomy, fertility, partners and pregnancy intention because administrative sex markers do not determine every applicable risk.
Paternal evidence is precautionary
The observed association may be confounded and causality is unconfirmed, yet the three-month contraception and sperm-donation advice still applies.
Forms support conversation
A signed acknowledgement does not replace accessible explanation, checking understanding or revisiting preference when circumstances change.
Licence follows formulation
Semi-sodium valproate has bipolar indications that sodium valproate and valproic acid may not share, despite a common active moiety.
Packaging carries safeguards
Original full-pack supply preserves outer-box warnings, patient information and traceability; exceptional split packs must retain the required safety material.
08Common pitfallsFrequent interpretation and management errors.
- 01
Starting valproate in an under-55 patient after only one specialist decision or without documenting the exception basis.
- 02
Treating a historical risk form as permanent evidence that current contraception, pregnancy intent and preference are unchanged.
- 03
Telling a concerned patient to stop valproate immediately without an urgent supervised relapse and reproductive plan.
- 04
Presenting the paternal neurodevelopmental association as proven causation rather than precautionary advice based on limited data.
- 05
Requiring two-specialist retrospective approval from every existing male patient under 55 despite the updated MHRA position.
- 06
Using a sodium valproate epilepsy licence as evidence that every formulation is licensed for bipolar mania.
- 07
Ordering routine valproate concentrations while missing due weight, blood-count, liver and reproductive-safety review.
- 08
Repackaging valproate without the required warnings, patient leaflet and current dispensing safeguards.